Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM
How I Practice Video ~ Efficacy of Quad Therapies
Pre-assessment

Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

1. What are your credentials? (Required.)

Hematologist

Medical Oncologist

Surgical Oncologist

Radiation Oncologist

Pathologist

Other MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

2. What is your community of practice?

Academic

Community

Other (please specify)

Question Title

3. In the IMROZ phase III trial of transplant-ineligible, newly diagnosed multiple myeloma (TIE NDMM), the addition of isatuximab to VRd (Isa VRd), followed by maintenance with Rd ± Isa, resulted in which of the following demonstrated outcomes? (Required.)

Significantly increased rates of MRD negativity that were not sustained beyond 12 months

Higher discontinuation rates secondary to increased toxicity

A statistically significant improvement in progression-free survival (PFS)

A statistically significant improvement in overall survival (OS)

Question Title

4. Which one of the following patients is the most suitable candidate for initiating a quadruplet induction regimen in newly diagnosed multiple myeloma (NDMM)? (Required.)

A 65 year old woman with ECOG PS 3, significant cardiac and renal impairment, limited social support, and transplant-ineligible (TIE)

A 75 year old man with ECOG PS 0, minimal comorbidities, eligible for autologous SCT and strong social support

An 80 year old woman with ECOG PS 1, diabetes and peripheral neuropathy, and borderline transplant eligibility (TE)

A 72 year old man with ECOG PS 2, hypertension and early CKD, marginal social support, and transplant-ineligible (TIE)

Question Title

5. Several phase III trials, including CEPHEUS and GMMG-HD7, have evaluated the impact of adding anti-CD38 antibodies to standard induction regimens in NDMM. Which of the following best describes the observed improvement in MRD-negativity rates following quadruplet induction therapy?

MRD-negativity rates are improved in both transplant-eligible (TE) and transplant-ineligible (TIE) patients, and progression-free survival (PFS) is prolonged

MRD-negativity rates are improved in both TE and TIE patients, but are not sustained over time

MRD-negativity rates are improved in both TE and TIE patients, but PFS is unaffected

MRD-negativity rates improve only in TE patients; no benefit is not observed in TIE patients

Question Title

6. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

Question Title

7. Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

🔗 Proceed to post-survey (post-survey completion must occur on or after activity launch date to be valid for claiming credit)

Four is More! Selecting and Optimizing Quadruplet Therapy in NDMMHow I Practice Video ~ Efficacy of Quad Therapies*Pre-assessment*

Question Title

* 1. What are your credentials? (Required.)

Question Title

* 2. What is your community of practice?

Question Title

* 3. In the IMROZ phase III trial of transplant-ineligible, newly diagnosed multiple myeloma (TIE NDMM), the addition of isatuximab to VRd (Isa VRd), followed by maintenance with Rd ± Isa, resulted in which of the following demonstrated outcomes? (Required.)

Question Title

* 4. Which one of the following patients is the most suitable candidate for initiating a quadruplet induction regimen in newly diagnosed multiple myeloma (NDMM)? (Required.)

Question Title

* 5. Several phase III trials, including CEPHEUS and GMMG-HD7, have evaluated the impact of adding anti-CD38 antibodies to standard induction regimens in NDMM. Which of the following best describes the observed improvement in MRD-negativity rates following quadruplet induction therapy?

Question Title

Question Title

* 7. Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.🔗 Proceed to post-survey (post-survey completion must occur on or after activity launch date to be valid for claiming credit)

Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM
How I Practice Video ~ Efficacy of Quad Therapies
Pre-assessment

1. What are your credentials? (Required.)

2. What is your community of practice?

3. In the IMROZ phase III trial of transplant-ineligible, newly diagnosed multiple myeloma (TIE NDMM), the addition of isatuximab to VRd (Isa VRd), followed by maintenance with Rd ± Isa, resulted in which of the following demonstrated outcomes? (Required.)

4. Which one of the following patients is the most suitable candidate for initiating a quadruplet induction regimen in newly diagnosed multiple myeloma (NDMM)? (Required.)

5. Several phase III trials, including CEPHEUS and GMMG-HD7, have evaluated the impact of adding anti-CD38 antibodies to standard induction regimens in NDMM. Which of the following best describes the observed improvement in MRD-negativity rates following quadruplet induction therapy?

7. Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

🔗 Proceed to post-survey (post-survey completion must occur on or after activity launch date to be valid for claiming credit)